For research use only
| Cat No. | ABC-X0002C |
| Product Type | Overexpression Stable Cell Lines |
| Cell Type | Lymphocyte |
| Species | Human |
| Host Cell | BAF3 |
| Source Organ | Lymphatic |
| Disease | Normal |
| Storage | Liquid Nitrogen |
AcceGen offers the LMNA-NTRK1 BAF3 cell line, supporting both polyclonal and monoclonal selection, facilitating the exploration of tumor mechanisms.
Human LMNA-NTRK1 BAF3 Cell Line is a genetically engineered model derived from selected murine Ba/F3 parental cell line based on customers’ requirement. LMNA-NTRK1 BAF3 fusion cell line is generated by stable integration of exogenous human LMNA-NTRK1 fusion gene into Ba/F3 host cells using our optimized transduction of lentiviral vectors. AcceGen offers generation of stable overexpression cell lines targeting any gene of your interest. Polyclonal or monoclonal is optional based on customers’ research needs.The LMNA-NTRK1 BAF3 Cell Line serves as a powerful tool to investigate TRK fusion-driven oncogenic mechanisms and therapeutic interventions.
| Species | Human |
| Cat.No | ABC-X0002C |
| Product Category | Transfected Stable Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Lymphocyte |
| Growth Mode | Suspension |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 °C, 5% CO₂ |
| Source Organ | Lymphatic |
| Disease | Normal |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Overexpression Stable Cell Lines |
| Host Cell | BAF3 |
| Quality Control | All cells test negative for mycoplasma, bacteria, yeast, and fungi. |
The Human LMNA NTRK1 BAF3 Cell Line serves as a valuable in vitro model for studying oncogenic fusion genes and targeted therapies related to NTRK1-driven malignancies. The LMNA-NTRK1 fusion has been implicated in various tumor types, including thyroid carcinoma and soft tissue sarcoma. This cell line enables evaluation of downstream signaling pathways such as MAPK and PI3K-AKT and assessment of selective TRK inhibitors. Researchers can also use it to validate diagnostic biomarkers and explore resistance mechanisms to targeted therapies.